SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance (AERO) is rallying amidst its Robinhood listing, driving community discussions around its role as Base's central liquidity hub and the implications of its anticipated merger into a "MetaDEX," while its revenue generation model is debated against other major DEXs.

Sperax is redefining financial autonomy through programmable agents that manage capital, optimize yield, and protect against risk, all transparently on-chain. Founded in 2019, Sperax is backed by leading investors including Jump Trading, Polychain Capital, Amber Group. Sperax offers a new standard in automated, user-driven finance.  The SperaxOS ecosystem is powered by USDs and SPA on Arbitrum, BNB Chain, and other EVM networks. Anchored by two native assets: USDs, a gas-free, auto-yield stablecoin backed by on-chain collateral, and SPA, the governance and value-capture token. Sperax builds open-source tools that turn idle capital into self-optimizing portfolios.  SperaxOS is a cross-chain financial operating system where AI-driven smart agents automate everything from yield farming to payroll, and Demeter, a no-code platform for launching liquidity farms. USDs automatically rebases yield to holders, while SPA lets users register agents, earn protocol fees, and vote on upgrades. Battle-tested through multiple market cycles: Sperax offers individuals, DAOs, and fintechs a borderless toolkit for passive income, risk-managed investing, and fully automated treasury operations, all governed on-chain by its community.

Sperax

Sperax (SPA) is trending as community chatter intensifies around the imminent launch of its SperaxOS, with investors accumulating on the belief that evolving stablecoin regulations, particularly the GENIUS Act, will significantly benefit its USDS stablecoin and drive a major rally.

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

ZIM Integrated Shipping is trending amid active acquisition interest from multiple shipping giants, including Hapag-Lloyd and MSC, after its board rejected an initial offer as too low. The community is buzzing with expectations of a bidding war, a special dividend, and a significant short squeeze, though national security and union concerns regarding foreign ownership are key discussion points.

Lithium Argentina AG is a resource and materials company that engages in the production of lithium carbonate for lithium-ion batteries and electric vehicles. Its projects include: Cauchari-Olaroz and Pastos Grandes. The company was founded by Raymond Edward Flood, Jr. on November 27, 2007 and is headquartered in Zug, Switzerland.

Lithium Argentina AG

Lithium Argentina (LAR) is trending as rising global lithium prices, strong production at its Cauchari-Olaroz project, and recent analyst upgrades are driving community discussions about its significant upside potential as a key producer in the strengthening critical minerals market.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Delta Air Lines is soaring after reporting strong Q4 earnings and an optimistic 2026 outlook, fueled by robust international and premium travel demand. The community is highlighting the airline's strategic focus on high-margin segments, even as some ponder if the current rally is overextended.

ASP Isotopes, Inc. is a pre-commercial stage advanced materials company, which engages in the development of technology and processes that will allow for the enrichment of natural isotopes into higher concentration products. Its products include medical, green energy, and Industrial isotopes. The company was founded by Paul E. Mann and Robert Ainscow on September 13, 2021 and is headquartered in Dallas, TX.

ASP Isotopes Inc

ASP Isotopes is trending as community conversation intensifies around the recently completed Renergen acquisition and the anticipated QLE spin-off, with many eager for updates on commercial isotope shipments amid broader sector momentum in critical materials and nuclear energy.

Ciena Corp. is a network technology company, which engages in the provision of hardware, software, and services to network operators, as well as enabling enhanced network capacity, service delivery, and automation. It operates through the following segments: Networking Platforms, Platform Software and Services, Blue Planet Automation Software and Services, and Global Services. The Networking Platforms segment consists of converged packet optical and packet networking portfolios. The Platform Software and Services segment provides analytics, data, and planning tools to assist customers in managing its networking platforms products. The Blue Planet Automation Software and Services segment enables customers to implement large-scale software and IT-led OSS transformations by transforming legacy networks into service ready networks. The Global Services segment offers a broad suite of value-added services. The company was founded by Patrick H. Nettles and Kevin Brian Kimberlin in 1992 and is headquartered in Hanover, MD.

CIENA Corp.

Ciena is experiencing significant interest as its imminent inclusion in the S&P 500 is set to drive index-related demand, fueling conversation around its substantial rally. The community is actively discussing the company's critical role as an AI infrastructure provider, with robust demand for network bandwidth driving its impressive performance, while also debating its valuation following a rapid ascent.

Ethereum Classic

Ethereum Classic is trending as the community grapples with deeply suppressed prices, with many long-term holders expressing both frustration and patient accumulation. Optimism for an upcoming "altcoin season" and potential catalysts like the Clarity Act and network developments are fueling hopes for a significant rebound.

Vanguard Group, Inc. - Vanguard S&P 500 ETF

Vanguard S&P 500 ETF

VOO is trending as positive market sentiment follows softer-than-expected inflation data, easing concerns around rate pressures and recent AI-led volatility. The community continues to favor this S&P 500 ETF as a stable core holding, attracting substantial inflows.

Royal Caribbean Group is a cruise company, which engages in the ownership and operation of the following global cruise brands: Royal Caribbean International, Celebrity Cruises, and Silversea Cruises. The firm also holds interest in TUI Cruises GmbH, which operates the German brands TUI Cruises and Hapag-Lloyd Cruises. The company was founded by Arne Wilhelmsen in 1968 and is headquartered in Miami, FL.

Royal Caribbean Group

Royal Caribbean Group is trending following a substantial dividend increase and robust future guidance, driven by record bookings and sustained demand extending into 2026. The community is actively discussing the company's strong cash flow and strategic expansion, solidifying its position as a leading player in the travel sector amidst market movements.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Needham raised its 2026 e-commerce revenue forecast from $1.05 billion to $1.45 billion.</li><li>The firm noted that AppLovin’s share price has recently retreated from its peak a month ago, presenting a potential buying opportunity for investors.</li><li>Needham also highlighted the potential for upside beyond current projections, suggesting that AppLovin could follow a growth trajectory similar to TikTok's.</li></ul>AppLovin (APP) has received a bullish upgrade from Needham, which raised its rating to ‘Buy’ from ‘Hold’ and set a $700 price target, reflecting renewed confidence in the company’s e-commerce growth potential for 2026.&nbsp;The price target implies a potential 33% upside from the company’s Friday closing price.&nbsp;<h2 class="st-heading-2">Revenue Growth Outlook</h2>The move comes after Needham observed strong performance in AppLovin’s e-commerce segment, particularly driven by its self-service advertising platform. The firm raised its 2026 e-commerce revenue forecast from $1.05 billion to $1.45 billion, citing increased advertiser adoption and higher spending that could offset the usual seasonal dip in the first quarter.&nbsp;<a href="https://stocktwits.com/symbol/APP">AppLovin stock</a> traded over 5% higher on Monday morning. On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory while message volume changed to ‘high’ from ‘extremely high’ levels in 24 hours.&nbsp;The firm noted that AppLovin’s share price has recently retreated from its peak a month ago, presenting a potential buying opportunity for investors. Needham also highlighted the potential for upside beyond current projections, suggesting that AppLovin could follow a growth trajectory similar to TikTok in the e-commerce and digital advertising spaces.<h2 class="st-heading-2">Fourth-Quarter Earnings&nbsp;</h2>The company is scheduled to report its fourth-quarter earnings on February 11 and expects revenue in the range of $1.57 billion and $1.6 billion. Analysts see a revenue of $1.61 billion and earnings per share of $2.95.&nbsp;Founded in 2012, AppLovin specializes in mobile advertising technology and software solutions for app developers. Its platform connects advertisers with consumers through programmatic campaigns while enabling app publishers to monetize effectively.&nbsp;However, last week, Capitalwatch released a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.capitalwatch.com/">report</a> accusing AppLovin’s main shareholders, Hao Tang and Ling Tang, of using the company to move large amounts of illegal money. The report claimed that criminal groups paid AppLovin huge advertising fees through its AXON and Array systems to launder illicit funds.&nbsp;APP stock has gained over 58% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/inmd-stock-jumped-today-what-is-powering-the-rally/cmy7tBNR4h4">INMD Stock Jumped Nearly 13% Today – What’s Powering The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the AppLovin Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

AppLovin Stock Gets A Needham Upgrade – Why Does The Firm See A 33% Upside Potential For The Stock?

Needham said it observed strong performance in AppLovin’s e-commerce segment, particularly driven by its self-service advertising platform.

Equity

Needham said it observed strong performance in AppLovin’s e-commerce segment, particularly driven by its self-service advertising platform.


<ul class="summary-bullets"><li>It is now unclear when the company would apply for approval of the gene therapy, it said.</li><li>uniQure, however, added that it intends to communicate with the FDA to determine a path forward toward approval of the therapy.&nbsp;</li><li>uniQure CEO termed the meeting outcome “unexpected.” &nbsp;</li></ul>uniQure N.V. (QURE) no longer believes that the U.S. Food and Drug Administration considers data from an early-to mid-stage trial of its investigational gene therapy for Huntington’s disease sufficient for approval, the company said on Monday.The company recently met with the agency, and although the minutes of the meeting have not been received, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/03/3179114/0/en/uniQure-Provides-Regulatory-Update-on-AMT-130-for-Huntington-s-Disease.html">believes</a> that the FDA no longer considers the data from the AMT-130 trial adequate to provide primary evidence in support of an application for approval.As a result, it is now unclear when the company would apply for approval of the gene therapy, it said. uniQure, however, added that it intends to communicate with the FDA to determine a path forward toward approval of the therapy.<h2 class="st-heading-2">CEO Reacts</h2>uniQure CEO termed the meeting outcome “unexpected.”“We are surprised by the FDA’s feedback at the recent pre-BLA meeting, which is a drastic change from the guidance the FDA provided in November 2024 that data from the ongoing Phase I/II studies, compared to a natural history external control, may serve as the primary basis for a BLA submission under the Accelerated Approval pathway,” CEO Matt Kapusta said.The company also stated that it intends to engage in further communications with other regulatory agencies while working with the FDA.<h2 class="st-heading-2">Expert Take</h2>Stifel analyst Annabel Samimy said that the news regarding the FDA's reversal on the approvability of uniQure's AMT-130 based on early to mid-stage trial data on the surface injects another layer of uncertainty into the workings of the FDA and their receptivity to gene therapy, more specifically.The analyst, however, does not expect this to impact Regenxbio’s (RGNX) rare disease programs. Meanwhile, Raymond James added that it does not expect the meeting outcome to impact Biohaven (BHVN) either.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>QURE stock traded 55% lower at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/QURE">QURE stock</a> fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.QURE stock is up 72% this year and approximately 445% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tg-therapeutics-stock-soars-after-company-ups-guidance-for-multiple-sclerosis-drug/cL2NEPSR3zl">TG Therapeutics Stock Soars After Company Ups Guidance For Multiple Sclerosis Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the uniQure logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

uniQure Stock Tumbled 55% Today: What’s The FDA Angle?

The company recently met with the FDA and believes that the agency no longer considers the data from an early-to-mid-stage trial of its investigational gene therapy sufficient for approval.

Alger Funds - Alger Mid Cap 40 ETF

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

Current Price	$20.66
Prev Close	$20.38
Open	$20.61
Dividend Yield	N/A
50-Day Moving Average	$21.33
Beta	N/A
Avg. Volume	37,045.85
PE Ratio	N/A

52-Week High	$23.36
52-Week Low	$13.56
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

FRTY
Alger Funds - Alger Mid Cap 40 ETF

Feed

News

Sentiment

Fundamentals

Info

Latest FRTY News

FRTYAlger Funds - Alger Mid Cap 40 ETF